

# Xbrane invites to a webcast related to the announcement of the commercialization and license agreement

**Xbrane Biopharma AB (publ) ("Xbrane" eller "Company") (Nasdaq Stockholm: XBRANE), a leading Biosimilar Developer invites to a webcast related to the announcement of the commercialization and license agreement for Xcimzane™**

## Webcast

Xbrane will host a webcast for investors, analysts, and media, where CEO Martin Åmark will present and reason around the entered commercialization and license agreement for Xcimzane™. The presentation will be held in English.

The webcast is held tomorrow Tuesday February 8th, 10:00-10:45. Please register using the following link:

## Weblink

<https://tv.streamfabriken.com/xbrane-biopharma-press-conference-2022>

## Participant dial in number

SE: +46 8 505 583 56

UK: +44 3 333 009 032

US: +1 631 913 14 22 PIN US: 419 68 092#

## Contacts

---

Martin Åmark, CEO

M: +46 76 309 37 77

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR

M: +46 76 325 60 90

E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

---

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting €28 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com)

## Attachments

---

[Xbrane invites to a webcast related to the announcement of the commercialization and license agreement](#)